tiprankstipranks
Johnson & Johnson (MX:JNJ)
NYSE:JNJ
Mexico Market
JNJ
Johnson & Johnson
RESEARCH TOOLSreports

Johnson & Johnson (JNJ) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

JNJ Analyst Ratings

Strong Buy
18Ratings
Strong Buy
14 Buy
4 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Johnson
& Johnson
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JNJ Stock 12 Month Forecast

Average Price Target

$4,890.50
▲(6.08% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $4,890.50 with a high forecast of $5,319.33 and a low forecast of $4,447.31. The average price target represents a 6.08% change from the last price of $4,609.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2776":"$2,776","3412":"$3,412","4048":"$4,048","4684":"$4,684","5320":"$5,320"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5319.33447145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.32K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4890.50480721353,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.89K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4447.31242695,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.45K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2776,3412,4048,4684,5320],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4447,4514.10265165,4581.2053033,4648.30795495,4715.4106066,4782.51325825,4849.6159099,4916.71856155,4983.8212132,5050.9238648499995,5118.0265165,5185.12916815,5252.2318198,{"y":5319.33447145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4447,4481.115754401041,4515.231508802081,4549.347263203123,4583.463017604163,4617.578772005204,4651.694526406244,4685.810280807285,4719.926035208326,4754.041789609367,4788.157544010407,4822.273298411448,4856.389052812488,{"y":4890.50480721353,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4447,4447.024032842308,4447.048065684616,4447.072098526924,4447.0961313692305,4447.120164211538,4447.144197053846,4447.168229896154,4447.192262738462,4447.21629558077,4447.240328423077,4447.264361265385,4447.2883941076925,{"y":4447.31242695,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2777.456,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3084.761,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3262.359,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3326.562,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3433.454,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3748.344,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3696.727,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3938.481,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4267.389,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4349.913,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3991.977,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3885,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4447,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$5,319Average Price Target$4,891Lowest Price Target$4,447
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on MX:JNJ
Louise Chen
Scotiabank
Scotiabank
$5,319.33
Buy
15.39%
Upside
Assigned
07/30/26
Analysts' Top Healthcare Picks: Boston Scientific (BSX), Intuitive Surgical (ISRG)
Bank of America Securities Analyst forecast on MX:JNJ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$4,586.84
Hold
-0.50%
Downside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Nurix Therapeutics (NASDAQ: NRIX) and Johnson & Johnson (NYSE: JNJ)
Morgan Stanley Analyst forecast on MX:JNJ
Terence Flynn
Morgan Stanley
Morgan Stanley
$5,127.49
Buy
11.23%
Upside
Reiterated
07/28/26
Johnson & Johnson: Talc Settlement Progress Supports Buy Rating with Unchanged $294 Price Target
Argus Research Analyst forecast on MX:JNJ
David Toung
Argus Research
Argus Research
$5,057.73→$5,232.13
Buy
13.50%
Upside
Assigned
07/28/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Medios AG (Other OTC: MEDOF) and NeuroPace (NASDAQ: NPCE)
Goldman Sachs Analyst forecast on MX:JNJ
Asad Haider
Goldman Sachs
Goldman Sachs
$4,918.2
Buy
6.69%
Upside
Reiterated
07/27/26
Johnson & Johnson: Talc Settlement Progress Removes Major Overhang; Buy Rating Reiterated with Unchanged $282 Price Target
Guggenheim Analyst forecast on MX:JNJ
Vamil Divan
Guggenheim
Guggenheim
$4,708.92
Buy
2.15%
Upside
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH), Johnson & Johnson (NYSE: JNJ) and Thermo Fisher (NYSE: TMO)
Wells Fargo Analyst forecast on MX:JNJ
Larry Biegelsen
Wells Fargo
Wells Fargo
$4,743.8
Buy
2.90%
Upside
Reiterated
07/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Molina Healthcare (NYSE: MOH) and Johnson & Johnson (NYSE: JNJ)
Citi Analyst forecast on MX:JNJ
Joanne Wuensch
Citi
Citi
$4,970.53→$5,197.25
Buy
12.74%
Upside
Reiterated
07/22/26
Citi Sticks to Its Buy Rating for Johnson & Johnson (JNJ)
RBC Capital Analyst forecast on MX:JNJ
Trung Huynh
RBC Capital
RBC Capital
$5,005.41
Buy
8.58%
Upside
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)
Leerink Partners Analyst forecast on MX:JNJ
David Risinger
Leerink Partners
Leerink Partners
$4,621.72→$4,813.56
Buy
4.42%
Upside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
Raymond James Analyst forecast on MX:JNJ
Jayson Bedford
Raymond James
Raymond James
$4,499.63→$4,621.72
Buy
0.25%
Upside
Reiterated
07/16/26
Johnson & Johnson price target raised to $265 from $258 at Raymond JamesJohnson & Johnson price target raised to $265 from $258 at Raymond James
J.P. Morgan Analyst forecast on MX:JNJ
Chris Schott
J.P. Morgan
J.P. Morgan
$4,534.51→$4,708.92
Hold
2.15%
Upside
Assigned
07/16/26
Johnson & Johnson price target raised to $270 from $260 at JPMorganJohnson & Johnson price target raised to $270 from $260 at JPMorgan
Freedom Capital Markets Analyst forecast on MX:JNJ
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
$4,883.32
Buy
5.93%
Upside
Upgraded
07/16/26
Johnson & Johnson upgraded to Buy from Hold at Freedom BrokerJohnson & Johnson upgraded to Buy from Hold at Freedom Broker
Stifel Nicolaus Analyst forecast on MX:JNJ
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$4,534.51
Hold
-1.64%
Downside
Reiterated
07/15/26
JNJ: Strong Innovative Medicine Drives Guidance Raise but Mixed MedTech Keeps Risk/Reward Balanced, Supporting Hold Rating
TD Cowen Analyst forecast on MX:JNJ
Steve Scala
TD Cowen
TD Cowen
$4,360.11→$5,232.13
Buy
13.50%
Upside
Reiterated
07/13/26
Johnson & Johnson price target raised to $300 from $250 at TD CowenJohnson & Johnson price target raised to $300 from $250 at TD Cowen
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on MX:JNJ
Louise Chen
Scotiabank
Scotiabank
$5,319.33
Buy
15.39%
Upside
Assigned
07/30/26
Analysts' Top Healthcare Picks: Boston Scientific (BSX), Intuitive Surgical (ISRG)
Bank of America Securities Analyst forecast on MX:JNJ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$4,586.84
Hold
-0.50%
Downside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Nurix Therapeutics (NASDAQ: NRIX) and Johnson & Johnson (NYSE: JNJ)
Morgan Stanley Analyst forecast on MX:JNJ
Terence Flynn
Morgan Stanley
Morgan Stanley
$5,127.49
Buy
11.23%
Upside
Reiterated
07/28/26
Johnson & Johnson: Talc Settlement Progress Supports Buy Rating with Unchanged $294 Price Target
Argus Research Analyst forecast on MX:JNJ
David Toung
Argus Research
Argus Research
$5,057.73→$5,232.13
Buy
13.50%
Upside
Assigned
07/28/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Medios AG (Other OTC: MEDOF) and NeuroPace (NASDAQ: NPCE)
Goldman Sachs Analyst forecast on MX:JNJ
Asad Haider
Goldman Sachs
Goldman Sachs
$4,918.2
Buy
6.69%
Upside
Reiterated
07/27/26
Johnson & Johnson: Talc Settlement Progress Removes Major Overhang; Buy Rating Reiterated with Unchanged $282 Price Target
Guggenheim Analyst forecast on MX:JNJ
Vamil Divan
Guggenheim
Guggenheim
$4,708.92
Buy
2.15%
Upside
Reiterated
07/23/26
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH), Johnson & Johnson (NYSE: JNJ) and Thermo Fisher (NYSE: TMO)
Wells Fargo Analyst forecast on MX:JNJ
Larry Biegelsen
Wells Fargo
Wells Fargo
$4,743.8
Buy
2.90%
Upside
Reiterated
07/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Molina Healthcare (NYSE: MOH) and Johnson & Johnson (NYSE: JNJ)
Citi Analyst forecast on MX:JNJ
Joanne Wuensch
Citi
Citi
$4,970.53→$5,197.25
Buy
12.74%
Upside
Reiterated
07/22/26
Citi Sticks to Its Buy Rating for Johnson & Johnson (JNJ)
RBC Capital Analyst forecast on MX:JNJ
Trung Huynh
RBC Capital
RBC Capital
$5,005.41
Buy
8.58%
Upside
Reiterated
07/21/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)
Leerink Partners Analyst forecast on MX:JNJ
David Risinger
Leerink Partners
Leerink Partners
$4,621.72→$4,813.56
Buy
4.42%
Upside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
Raymond James Analyst forecast on MX:JNJ
Jayson Bedford
Raymond James
Raymond James
$4,499.63→$4,621.72
Buy
0.25%
Upside
Reiterated
07/16/26
Johnson & Johnson price target raised to $265 from $258 at Raymond JamesJohnson & Johnson price target raised to $265 from $258 at Raymond James
J.P. Morgan Analyst forecast on MX:JNJ
Chris Schott
J.P. Morgan
J.P. Morgan
$4,534.51→$4,708.92
Hold
2.15%
Upside
Assigned
07/16/26
Johnson & Johnson price target raised to $270 from $260 at JPMorganJohnson & Johnson price target raised to $270 from $260 at JPMorgan
Freedom Capital Markets Analyst forecast on MX:JNJ
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
$4,883.32
Buy
5.93%
Upside
Upgraded
07/16/26
Johnson & Johnson upgraded to Buy from Hold at Freedom BrokerJohnson & Johnson upgraded to Buy from Hold at Freedom Broker
Stifel Nicolaus Analyst forecast on MX:JNJ
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$4,534.51
Hold
-1.64%
Downside
Reiterated
07/15/26
JNJ: Strong Innovative Medicine Drives Guidance Raise but Mixed MedTech Keeps Risk/Reward Balanced, Supporting Hold Rating
TD Cowen Analyst forecast on MX:JNJ
Steve Scala
TD Cowen
TD Cowen
$4,360.11→$5,232.13
Buy
13.50%
Upside
Reiterated
07/13/26
Johnson & Johnson price target raised to $300 from $250 at TD CowenJohnson & Johnson price target raised to $300 from $250 at TD Cowen
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

3 Months
Asad HaiderGoldman Sachs
Success Rate
12/14 ratings generated profit
86%
Average Return
+9.76%
Copying Asad Haider's trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +9.76% per trade.
1 Year
Asad HaiderGoldman Sachs
Success Rate
14/14 ratings generated profit
100%
Average Return
+32.49%
Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.49% per trade.
2 Years
Asad HaiderGoldman Sachs
Success Rate
14/14 ratings generated profit
100%
Average Return
+37.16%
Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +37.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JNJ Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
23
24
27
26
37
Hold
14
12
12
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
37
36
39
35
45
In the current month, JNJ has received 37 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. JNJ average Analyst price target in the past 3 months is 4,890.50.
Each month's total comprises the sum of three months' worth of ratings.

JNJ Financial Forecast

JNJ Earnings Forecast

Next quarter’s earnings estimate for JNJ is $52.41 with a range of $43.02 to $55.17. The previous quarter’s EPS was $50.31. JNJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.
Next quarter’s earnings estimate for JNJ is $52.41 with a range of $43.02 to $55.17. The previous quarter’s EPS was $50.31. JNJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Sales Forecast

Next quarter’s sales forecast for JNJ is $439.27B with a range of $434.31B to $443.23B. The previous quarter’s sales results were $439.19B. JNJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.
Next quarter’s sales forecast for JNJ is $439.27B with a range of $434.31B to $443.23B. The previous quarter’s sales results were $439.19B. JNJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Stock Forecast FAQ

What is MX:JNJ’s average 12-month price target, according to analysts?
Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 4,890.50.
    What is MX:JNJ’s upside potential, based on the analysts’ average price target?
    Johnson & Johnson has 6.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Johnson & Johnson a Buy, Sell or Hold?
          Johnson & Johnson has a consensus rating of Strong Buy, which is based on 14 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Johnson & Johnson’s share price target?
            The average share price target for Johnson & Johnson is 4,890.50. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $5,319.33 ,and the lowest forecast is $4,447.31. The average share price target represents 6.08% Increase from the current price of $4,609.99.
              What do analysts say about Johnson & Johnson?
              Johnson & Johnson’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of Johnson & Johnson?
                To buy shares of MX:JNJ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.